Global Influenza Vaccines Market and Forecast to 2021

The global influenza vaccines market is anticipated to reach nearly US$ 5 Billion by 2021. Influenza is a highly communicable disease and typically has the most severe impact on children and the elderly. Influenza viruses are considered as a major cause of morbidity and mortality worldwide. The vast population base together with significantly low vaccination coverage in emerging markets, rising government support for immunization and growing awareness of the value of influenza vaccine in preventing disease are the prominent factors that will fuel the growth of the influenza vaccines market.

Geographically, North America is the largest market for influenza vaccines capturing around 50% market share in 2015. Asia is the second largest market for influenza vaccines. Europe is the third largest market for influenza vaccines, followed by Latin America with around XX% share in 2015. Australasia accounted for least share of the influenza vaccines market in 2015.

Request a sample copy of Report @ http://www.orbisresearch.com/contacts/request-sample/175215

On the basis of country, United States captures majority of the influenza vaccines market share. Japan is the second leading market for influenza vaccines with around XX% share in 2015. China and India are the third and fourth leading market for influenza vaccines with XX% and XX% market share respectively in 2015. Brazil, Germany, France, UK, Italy, Spain and South Korea are the other leading market for influenza vaccines.

In the influenza vaccines brand sales segment, Sanofi’s Fluzone holds the maximum share of the market being followed by Fluvirin/Flucelvax. GSK’s Fluarix/FluLaval accounts for the third highest share of the influenza vaccines market. FluMist/Fluenz and Afluria/Fluvax stands at the fourth and fifth position in the influenza vaccines market, while Flublok has captured least share of the influenza vaccines market.

The Influenza Vaccines Market have been analyzed from 5 viewpoints:
1. Influenza Vaccines Market, Persons Vaccinated and Forecast - By Region (2011 - 2021)
2. Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (2011 - 2021)
3. Global - Influenza Vaccines Brand Sales and Forecast to 2021
4. Global Influenza Vaccines Market - Major Deals
5. Global Influenza Vaccines Market - Driving Factors and Challenges

Influenza Vaccines Market, Persons Vaccinated and Forecast - By Region
1. North America
2. Latin America
3. Europe
4. Asia
5. Australasia

Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (25 Countries Covered)
1. United States
2. Canada
3. Brazil
4. Mexico
5. Germany
6. France
7. Italy
8. Spain
9. United Kingdom
10. Netherlands
11. Ireland
12. Denmark
13. Luxembourg
14. Sweden
15. Australia
16. New Zealand
17. Japan
18. China
19. India
20. South Korea
21. Singapore
22. Hong Kong
23. Malaysia
24. Thailand
25. Indonesia

Browse Full Report with TOC@ http://www.orbisresearch.com/reports/index/global-influenza-vaccines-market-and-forecast-to-2021-size-share-growth-and-trends-analysis

Global Influenza Vaccines Brand Sales and Forecast - 7 Brands Analyzed
1. Fluarix/FluLaval
2. Fluzone
3. Fluvirin/Flucelvax
4. Influvac
5. Afluria/Fluvax
6. FluMist/Fluenz
7. Flublok

Check discount available for Report@ http://orbisresearch.com/contacts/discount/175215

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: sales@orbisresearch.com

This release was published on openPR.